CONCI, NICOLE
CONCI, NICOLE
Borsisti
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
2021 Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC
2022 Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Conci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
2021 Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A.
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
2021 Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A.
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter
2020 Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. | Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S..., Ambrosini V, Ardizzoni A. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience | Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. | 2020-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC | Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Co...nci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea | 2022-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 12. Dall'Olio_Monitoring Tumor Growth Rate to predict Immune Checkpoint Inhibitors’ treatment outcome in advanced NSCLC.pdf |
| PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis | Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors | Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontan...a F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A. | 2021-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter | Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A. | 2020-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |